ERBB2 and breast carcinoma: Notably, in previous studies, pertuzumab was far more effective than trastuzumab in inhibiting the proliferation of breast cancer cell lines expressing varying levels of HER2/neu (Agus et al, 2002; Nahta et al, 2004).